Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours

(Oxford, UK and Conshohocken, US, 20 August 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, today announces that it has dosed the first patient in a Phase I study, part of an ongoing collaboration with GlaxoSmithKline (GSK).